Toxicokinetics

Principles and Methods of Toxicology: Fifth Edition

Volumn , Issue , 2007, Pages 179-230

  Renwick, Andrew Gordon ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056965467     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (140)

1. Peck, C. C., Barr, W. H., Benet, L. Z., Collins, J., Desjardins, R. E., Furst, D. E., Harter, J. G., Levy, G., Ludden, T., Rodman, J. H., Sanathanan, L., Schentag, J. J., Shah, V. P., Sheiner, L. B., Skelly, J. P., Stanski, D. R., Temple, R. J., Viswanathan, C. T., Weissinger, J., and Yacobi, A. (1992): Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther., 51:465-173.
2. Abdel-Rahman, S. M., and Kauffman, R. E. (2004): The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Ann. Rev. Pharmacol. Toxicol., 44:111-136.
3. WHO (1986): Principles of Toxicokinetic Studies, Vol. 57, Environmental Health Criteria. World Health Organization, Geneva, Switzerland.
4. Edler, L., Poirier, K., Dourson, M., Kleiner, J., Mileson, B., Nordmann, H., Renwick, A., Slob, W., Walton, K., and Würtzen. G. (2002): Mathematical modelling and quantitative methods. Food Chem. Toxicol., 40:193-236.
5. WHO (1987): Principles for the Safety Assessment of Food Additives and Contaminants in Food, Vol. 70, Environmental Health Criteria. World Health Organization, Geneva, Switzerland.
6. Renwick, A. G. (1991): Safety factors and establishment of acceptable daily intakes. Food Addit. Contamin., 8:135-150.
7. Renwick, A. G. (1993): Data derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit. Contamin., 10:275-305.
8. WHO (1994): Assessing Human Health Risks of Chemicals: Derivation of Guidance Values for Health-Based Exposure Limits, Vol. 170, Environmental Health Criteria. World Health Organization, Geneva, Switzerland.
9. WHO (1999): Assessing Human Health Risks of Chemicals: Principles for the Assessment of Risk to Human Health from Exposure to Chemicals, Vol. 210, Environmental Health Criteria. World Health Organization, Geneva, Switzerland.
10. WHO (2005): Chemical-Specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/Concentration-Response Assessment, Harmonization Document No. 2. World Health Organization, Geneva.
11. Spurring, N. W., and Carey, P. F. (1992): Dose selection for toxicity studies: a protocol for determining the maximum repeatable dose. Human Exp. Toxicol., 11:449-157.
12. Anderson, M. W., Hoel, D. G., and Kaplan, N. L. (1980): A general scheme for the incorporation of pharmacokinetics in low-dose risk estimation for chemical carcinogens: example-vinyl chloride. Toxicol. Appl. Pharmacol., 55: 154-161.
13. Campbell, D. B., and Ings, R. M. J. (1988): New approaches to the use of pharmacokinetics in toxicology and drug development. Human Toxicol., 7:469-479.
14. Garattini, S. (1987): Toxic effects of chemicals: difficulties in extrapolating data from animals to man. CRC Crit. Rev. Toxicol., 16:1-29.
15. Munro, A. M. (1990): Interspecies comparisons in toxicology: the utility and futility of plasma concentrations of the test compound. Reg. Toxicol. Pharmacol., 12:137-160.
16. Cohn, V. H. (1971): Transmembrane movement of drug molecules. In: Fundamentals of Drug Metabolism and Drug Disposition, edited by B. N. LaDu, H. G. Mandel, and E. L. Way. Williams & Wilkins, Baltimore, MD, pp. 3-13.
17. Ochsenfahrt, H., and Winne, D. (1972): Solvent drag influence on the intestinal absorption of basic drugs. Life Sci., 11:1115-1122.
18. Smith, J. W. (1965): Observations on the flora of the alimentary tract of animals and factors affecting its composition. J. Pathol. Bacteriol., 89:95-122.
19. Scheline, R. R. (1973): Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev., 25:451-523.
20. Renwick, A. G. (1982): First pass metabolism within the lumen of the gastrointestinal tract. In Presystemic Drug Elimination, edited by C. F. George, D. G. Shand, and A. G. Renwick. Butterworth, Boston, pp. 3-28.
21. Caldwell, J., and Varwell Marsh, M. (1982): Metabolism of drugs by the gastrointestinal tract. In: Presystemic Drug Elimination, edited by C. F. George, D. G. Shand, and A. G. Renwick. Butterworth, Boston, pp. 29-42.
22. Gibaldi, M., and Perrier, D. (1974): Route of administration and drug disposition. Drug Metab. Rev., 3:185-199.
23. Gibaldi, M., and Perrier, D. (1982): Pharmacokinetics, 2nd ed. Marcel Dekker, New York.
24. Su, K. S. E., Campanale, K. M., and Gries, C. L. (1984): Nasal drug delivery system of a quaternary ammonium compound: clofilium tosylate. J. Pharm. Sci., 73: 1251-1254.
25. Taylor, A. E., and Gaar, K. A. (1970): Estimation of equivalent pore radii of pulmonary capillary and alveolar membranes. Am. J. Physiol., 218:1133.
26. Richards, R., Dickson, C. R., Renwick, A. G., Lewis, R. A., and Holgate, S. T. (1987): Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique. J. Pharmacol. Exp. Therap., 241:1028-1032.
27. McCarley, K. D., and Bunge, A. L. (2001): Pharmacokinetic models of dermal absorption. J. Pharm. Sci., 90:1699-1719.
28. Guy, R. H., Hadgraft, J., and Marbach, H. I. (1984): Percutaneous absorption in man: a kinetic approach. Toxicol. Appl. Pharmacol., 78:123-129.
29. Bard, P. (1956): In: Medical Physiology, 10th ed. Henry Kimpton, London, p. 221.
30. Butler, T. C. (1971): The distribution of drugs. In: Fundamentals of Drug Metabolism and Drug Disposition, edited by B. N. LaDu, H. G. Mandel, and E. L. Way. Williams & Wilkins, Baltimore, MD, pp. 44-62.
31. Gehring, P. J., and Young, D. J. (1978): Application of pharmacokinetic principles in practice. In: Proc. of the First Int. Congress on Toxicology: Toxicology as a Predictive Science, edited by G. L. Plaa and W. A. M. Duncan. Academic Press, New York, pp. 119-141.
32. 1 acid glycoprotein. N. Engl. J. Med., 299:1435-1439.
33. Anon. (1984): Clinical implications of drug protein binding. Clin. Pharmacokinet., 9(Suppl. 1):1-104.
34. Davison, C. (1971): Protein binding. In: Fundamentals of Drug Metabolism and Drug Disposition, edited by B. N. LaDu, H. G. Mandel, and E. L. Way. Williams & Wilkins, Baltimore, MD, pp. 63-75.
35. Lee, G., Dallas, S., Hong, M., and Bendayan, R. (2001): Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53:569-596.
36. de Boer, A. G., van der Sandt, I. C. J. and Gaillard, P. J. (2003): The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol., 43:629-656.
37. Fromm, M. F. (2004): Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci., 25: 423-429.
38. Gottesman, M. M. (2002): Mechanisms of cancer drug resistance. Annu. Rev. Med., 53:615-627.
39. Morris, M. M., Lee, H-J., and Predko, L. M. (2003): Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol. Rev., 55: 229-240.
40. Lee, W., and Kim, R. B. (2004): Transporters and renal drug elimination. Annu. Rev. Pharmacol. Toxicol., 44:137-166.
41. Daly, A. K. (2003): Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol., 17:27-11.
42. Dorne, J. L. C. M., Walton, K., and Renwick, A. G. (2004): Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem. Toxicol., 43:203-216.
43. Pirmohamed, M., and Park, B. K. (2001): Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci., 22:298-305.
44. Park, B. K., Kitteringham, N. R., Powell, H., and Pirmohamed, M. (2000): Advances in molecular toxicology: towards understanding idiosyncratic drug toxicity. Toxicology, 153:39-60.
45. Zhang, L., Brett, C. M., and Giacomini, K. M. (1998): Role of organic cation transporters in drug absorption and elimination. Annu. Rev. Pharmacol. Toxicol., 38:431-160.
46. Burckhardt, B. C., and Burckhardt, G. (2003): Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev. Physiol. Biochem. Pharmacol., 146:95-158.
47. Smith, R. L. (1973): The Excretory Function of Bile: The Elimination of Drugs and Toxic Substances in Bile. Chapman & Hall, London.
48. Hirom, P. C., Millburn, P., and Smith, R. L. (1976): Bile and urine as complementary pathways for the excretion of foreign organic compounds. Xenobiotica, 6:55-64.
49. Renwick, A. G. (1986): Gut bacteria and the enterohepatic circulation of foreign compounds. In: Microbial Metabolism in the Digestive Tract, edited by M. J. Hill. CRC Press, Boca Raton, FL, pp. 135-153.
50. Wilkinson, G. R. (1987): Clearance approaches in pharmacology. Pharmacol. Rev., 39:1-17.
51. Rescigno, A., and Segre, B. (1966): Drug and Tracer Kinetics. Blaisdell, London.
52. Solomon, S. (1977): Developmental changes in nephron number. proximal tubular length and superficial glomerular filtration rate of rats. J. Physiol. (Lond.), 272:573-589.
53. Weiner, I. M. (1967): Mechanisms of drug absorption and excretion: the renal excretion of drugs and related compounds. Annu. Rev. Pharmacol., 7:39-56.
54. Garrett, E. R. (1978): Pharmacokinetics and clearance related to renal processes. Int. J. Clin. Pharmacol., 16:155-172.
55. Rowland, M. et al. (1973): Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm., 1:123-136.
56. Travis, C. C., Quillen, J. L., and Arms, A. D. (1990): Pharmacokinetics of benzene. Toxicol. Appl. Pharmacol., 102:400-120.
57. Clewell, H. J., Gentry, P. R., Gearhart, J. M., Allen, B. C., and Andersen, M. E. (2001): Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci. Total Environ., 274:37-66.
58. Johanson, G., and Filser, J. G. (1996): PBPK model for butadiene metabolism to epoxides: quantitative species differences in metabolism, Toxicology, 113:40-47.
59. Jonsson, F., and Johanson, G. (2001): A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicol. Appl. Pharmacol., 174:99-112.
60. Mann, S., Droz, P.-O., and Vahter, M. (1996): A physiologically based pharmacokinetic model for arsenic exposure. Toxicol. Appl. Pharmacol., 140:471-486.
61. 8-toluene toxicokinetics assessed by a semi empirical physiologically based model. Toxicol. Appl. Pharmacol., 139:49-61.
62. Wang, X, Santostefano, M. J., Evans, M. V., Richardson, V. M., Diliberto, J. J., and Birnbaum, L. S. (1997): Determination of parameters responsible for pharmacokinetic behavior of TCDD in female Sprague-Dawley rats. Toxicol. Appl. Pharmacol., 147:151-168.
63. Bois, F. Y., Woodruff, T. J., and Spear, R. C. (1991): Comparison of three physiologically based pharmacokinetic models of benzene disposition. Toxicol. Appl. Pharmacol., 110:79-88.
64. Wagner, J. G. (1975): Do you need a pharmacokinetic model and, if so, which one? J. Pharmacokinet. Biopharm., 3:457-178.
65. Rowland, M., and Tozer, T. N. (1980): Clinical Pharmacokinetics: Concepts and Applications. Lea & Febiger, Philadelphia, PA.
66. Wagner, J. G. (1975): Fundamentals of Clinical Pharmacokinetic. Drug Intelligence Publications, Hamilton, IL.
67. Benet, L. Z., Levy, G., and Ferraiolo, B. L., Eds. (1984): Pharmacokinetics: A Modern View. Plenum Press, New York.
68. Rowland, M., and Tucker, G., Eds. (1986): Pharmacokinetics: Theory and Methodology. Pergamon Press, New York.
69. Gabrielsson, J., and Weiner, D. (1997): Pharmacokinetic! Pharmacodynamic Data Analysis: Concepts and Applications, 2nd ed. Swedish Pharmaceutical Society, Swedish Pharmaceutical Press, Sweden.
70. Riegelman, S., Loo, J. C. K., and Rowland, M. (1968): New method for calculating the intrinsic absorption rate of drugs. J. Pharm. Sci., 57:918-928.
71. Chan, K. K. H., and Gibaldi, M. (1985): Assessment of drug absorption after oral administration. J. Pharm. Sci., 74:388-393.
72. Park, B. K., Kitteringham, N. R., Pirmohamed, M., and Tucker, G. T. (1996): Relevance of induction of human drug-metabolising enzymes: pharmacological and toxicological implications. Br. J. Clin. Pharmacol., 41:477-491.
73. Santostefano, M. J., Wang, X., Richardson, V. M., Ross, D. G., DeVito, M. J., and Birnbaum, L. S. (1998): A pharmacodynamic analysis of TCDD-induced cytochrome P450 gene expression in multiple tissues: doseand time-dependent effects. Toxicol. Appl. Pharmacol., 151:294-310.
74. Benet, L. Z., and Galeazzi, R. L. (1979): Noncompartmental determination of the steady state volume of distribution. J. Pharm. Sci., 68:1071-1074.
75. Riegelman, S., and Collier, P. (1980): The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. Pharmacokinet. Biopharm., 8:509-534.
76. Waynforth, H. B. (1980): Experimental and Surgical Technique in the Rat. Academic Press, New York.
77. Cocchetto, D. M., and Bjornsson, T. D. (1983): Methods for vascular access and collection of body fluids from the laboratory rat. J. Pharm. Sci., 72:465-192.
78. Sanzgiri, U. Y., Kim, H. J., Muralidhara, S., Dallas, C. E., and Bruckner, J. V. (1995): Effect of route and pattern of exposure on the pharmacokinetics and acute hepatoxicity of carbon tetrachloride. Toxicol. Appl. Pharmacol., 134:148-154.
79. Huang, C. H., Kimcera, R., Nassar, R. B., and Hussain, A. (1985): Mechanisms of nasal absorption of drugs. I. Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J. Pharm. Sci., 74: 608-611.
80. Langenberg, J. P., Spruit, H. E. T., van der Wiel, H. J., Trap, H. C., Helmich, R. B., Bergers, W. W. A., van Helden, H. P. M., and Benschop, H. P. (1998): Inhalation toxicokinetics of soman stereoisomers in the atropinized guinea pig with nose-only exposure to soman vapour. Toxicol. Appl. Pharmacol., 151:79-87.
81. 14C]vinylidene chloride in rats following inhalation exposure. Toxicol. Appl. Pharmacol., 45:599-610.
82. Andersen, M. E., Gargas, M. L., Jones, R. A., and Jenkins, L. J. (1979): The use of inhalation techniques to assess the kinetic constants of 1,l-dichloroethylene metabolism. Toxicol. Appl. Pharmacol., 47:395-109.
83. McDougal, J. N., Jepson, G. W., Clewell, H. J., and Andersen, M. E. (1985): Dermal absorption of dihalomethane vapours. Toxicol. Appl. Pharmacol., 79:150-158.
84. Jepson, G. W., and McDougal, J. N. (1997): Physiologically based modeling of nonsteady state dermal absorption of halogenated methanes from an aqueous solution. Toxicol. Appl. Pharmacol., 144:315-324.
85. 63Ni clearance in rats. Toxicol. Appl. Pharmacol., 51:209-217.
86. Withey, J. R. (1978): Pharmacokinetic principles, in Proc. of the First Int. Congress on Toxicology: Toxicology as a Predictive Science, edited by G. L. Plaa and W. A. M. Duncan. Academic Press, New York, pp. 97-117.
87. Bakar, S. K., and Niazi, S. (1983): Simple reliable method for chronic cannulation of the jugular vein for pharmacokinetic studies in rats. J. Pharm. Sci., 72:1027-1029.
88. Light, H. G., Witmer, C., and Vars, H. M. (1959): Interruption of the enterohepatic circulation and its effects on rat bile, Am. J. Physiol., 197:1330-1332.
89. Bachmann, K. (1989): Predicting toxicokinetic parameters in humans from kinetic data acquired in three small mammalian species. J. Appl. Toxicol., 9:331-338.
90. Gerlowski, L. E., and Jain, R. K. (1983): Physiologically based pharmacokinetic modelling: principles and application. Pharm. Sci., 72:1103-1127.
91. Grene-Lerouge, N. A. M., Bazin-Redureau, M. I., Debray, M., and Scherrmann, J. M. G. (1996): Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol. Appl. Pharmacol., 138:84-89.
92. Mordenti, J. (1985): Pharmacokinetic scale up: accurate prediction of human pharmacokinetic profiles from animal data. J. Pharm. Sci., 74:1097-1099.
93. Scheuplein, R. J., Shoaf, S. E., and Brown, R. N. (1990): Role of pharmacokinetics in safety evaluation and regulatory decisions. Annu. Rev. Pharmacol. Toxicol., 30: 197-218.
94. Bopp, B. A., Sonders, R. C., and Kesterson, J. W. (1986): Toxicological aspects of cyclamate and cyclohexylamine. CRC Crit. Rev. Toxicol., 16:213-306.
95. Roberts, A., and Renwick, A. G. (1989): The pharmacokinetics and tissue concentrations of cyclohexylamine in rats and mice. Toxicol. Appl. Pharmacol., 98:230-242.
96. Buss, N. E., and Renwick, A. G. (1992): Blood pressure changes and sympathetic function in rats given cyclohex-ylamine by intravenous infusion. Toxicol. Appl. Pharmacol., 115:211-215.
97. Buss, N. E., Renwick, A. G., Donaldson, K. M., and George, C. F. (1992): The metabolism of cyclamate to cyclohexylamate and its cardiovascular consequences in human volunteers. Toxicol. Appl. Pharmacol., 115: 199-210.
98. JECFA (1982): Toxicological Evaluation of Certain Food Additives, WHO Food Additives Series No 17, WHO Technical Report Series No. 683, Twenty-Sixth Report of the Joint FAO!WHO Expert Committee on Food Additives, World Health Organization, Geneva, Switzerland (http://www.who.int!pcs!jecfa!JECFA_publications.htm).
99. SCF (1995): Opinion on Cyclamic Acid and Its Salts. Scientific Committee for Food of the European Commission (http:!!europa.eu.int!comm/food!fs!sc!scf!outcome_en.html).
100. Renwick, A. G., Thompson, J. P., O'Shaughnessy, M., and Walter, E. J. (2004): The metabolism of cyclamate to cyclohexylamine in humans during long-term administration. Toxicol. Appl. Pharmacol., 196:367-380.
101. SCF (2000): Opinion on Cyclamic Acid and Its Sodium and Calcium Salts. Scientific Committee on Food of the European Commission (ehttp://europa.eu.int/comm/food/fs/sc/scf/outcome_en.html).
102. JECFA (2002): Polychlorinated Dibenzodioxins, Polychlorinated Dibenzofurans, and Coplanar Polychlorinated Biphenyls, WHO Food Additives Series No. 48. Joint FAO/WHO Expert Committee on Food Additives, pp. 451-658.
103. SCF (2000): Opinion on the Risk Assessment of Dioxins and Dioxin-Like PCBs in Food. Scientific Committee for Food of the European Commission.
104. SCF (2001): Opinion on the Risk Assessment of Dioxins and Dioxin-Like PCBs in Food. Scientific Committee for Food of the European Commission.
105. van den Berg, M., Birnbaum, L., Bosveld, B. T. C., Brunström, B., Cook, P., Feeley, M., Giesy, J. P., Hanberg, A. et al. (1998): Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and for wildlife. Environ. Health Perspect., 106:775-792.
106. Gray, L. E., Ostby, J. S., and Kelce, W. R. (1997): A dose-response analysis of the reproductive effects of a single gestational dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin in male Long Evans Hooded rat offspring. Toxicol. Appl. Pharmacol., 146:11-20.
107. Gray, L. E., Jr., Wolf, C., Mann, P., and Ostby, J. S. (1997): In utero exposure to low doses of 2,3,7,8-tetrachlorod-ibenzo-p-dioxin alters reproductive development of female Long-Evans Hooded rat offspring. Toxicol. Appl. Pharmacol., 146:237-244.
108. Mably, T. A., Bjerke, D. L., Moore, R. W. (1992): Gendron-Fitzpatrick, A., and Peterson, R. E., In utero and lactational exposure of male rats to 2,3,7,8-tetrachlorodibenzo-p-dioxin. 3. Effects on spermatogenesis and reproductive capability. Toxicol. Appl. Pharmacol., 114:118-126.
109. Faqi, A. S., Dalsenter, P. R., Merker, H.-J., and Chahoud, I. (1998): Reproductive toxicity and tissue concentrations of low doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin in male offspring rats exposed throughout pregnancy and lactation. Toxicol. Appl. Pharmacol., 150: 383-392.
110. Ohsako, S., Miyabara, Y., Nishimura, N., Kurosawa, S., Sakaue, M., Ishimura, R., Sato, M., Takeda, K., Aoki, Y., Sone, H., Tohyama, C., and Yonemoto, J. (2001): Maternal exposure to a low dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) suppressed the development of reproductive organs of male rats: dose-dependent increase of mRNA levels of 5α-reductase type 2 in contrast to decrease of androgen receptor in the pubertal ventral prostate. Toxicol. Sci., 60:132-143.
111. Hurst, C. H., De Vito, M. J., Setzer, R. W., and Birnbaum, L. (2000): Acute administration of 2,3,7,8-tetrachlorod-ibenzo-p-dioxin (TCDD) in pregnant Long-Evans rats: association of measured tissue concentrations with developmental effects. Toxicol. Sci., 53:411-120.
112. Hurst, C. H., DeVito, M. J., and Birnbaum, L. S. (2000): Tissue disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in maternal and developing Long-Evans rats following subchronic exposure. Toxicol. Sci., 57:275-283.
113. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C., Gillette, J. R., and Brodie, B. B. (1973): Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther., 187:185-194.
114. Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., and Brodie, B. B. (1973): Acetaminophen-induced necrosis II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther., 187:195-202.
115. Potter, W. Z., Davis, D. C., Mitchell, J. R., Jollow, D. J., Gillette, J. R., and Brodie, B. B. (1973): Acetaminopheninduced hepatic necrosis. III. Cytochrome P-450-mediated covalent binding in vitro, J. Pharmacol. Exp. Ther., 187:203-210
116. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Gillette, J. R., and Brodie, B. B. (1973): Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther., 187:211-217.
117. Buss, N. E., Tembe, E. A., Prendergast, B. D., Renwick, A. G., and George, C. F. (1994): The teratogenic metabolites of vitamin A in women following supplements and liver. Human Exp. Toxicol., 13:33-43.
118. Tembe, E. A., Honeywell, R., Buss, N. E., and Renwick, A. G. (1996): All-trans-retinoic acid in maternal plasma and teratogenicity in rats and rabbits. Toxicol. Appl. Pharmacol., 141:456-472.
119. Schoenig, G. P., Goldenthal, E. I., Geil, R. G., Frith, C. H., Richter, W. R., and Carlborg, F. W. (1985): Evaluation of the dose response and in utero exposure to saccharin in the rat. Food Chem. Toxicol., 23:475-490
120. Sweatman, T. W., and Renwick, A. G. (1980): The tissue distribution and pharmacokinetics of saccharin in the rat. Toxicol. Appl. Pharmacol., 55:18-31.
121. Sims, J., and Renwick, A. G. (1983): The effects of saccharin on the metabolism of dietary tryptophan to indole, a known cocarcinogen for the urinary bladder of the rat. Toxicol. Appl. Pharmacol., 67:132-151.
122. Sims, J., and Renwick, A. G. (1985): The microbial metabolism of tryptophan in rats fed a diet containing 7.5% saccharin in a two-generation protocol. Food Chem. Toxicol, 23:437-444.
123. Lawrie, C. A., Renwick, A. G., and Sims, J. (1985): The urinary excretion of bacterial amino-acid metabolites by rats fed saccharin in the diet. Food Chem. Toxicol., 23: 445-450.
124. Renwick, A. G. (1985): The disposition of saccharin in animals and man: a review. Food Chem. Toxicol., 23: 429-435.
125. Roberts, A., and Renwick, A. G. (1985): The effect of saccharin on the microbial metabolism of tryptophan in man. Food Chem. Toxicol., 23:451-455.
126. Sauerhoff, M. W., Braun, W. H., Blau, G. E., and Gehring, P. J. (1976): The dose-dependent pharmacokinetic profile of 2,4,5-trichlorophenoxy acetic acid following intravenous administration to rats. Toxicol. Appl. Pharmacol., 36:491-501.
127. Eisenbrand, G., Pool-Zobel, B., Baker, V., Balls, M., Blaauboer, B. J., Boobis, A., Carere, A., Kevekordes, S., Lhugue-not, J.-C., Pieters, R., and Kleiner, J. (2002): Methods of in vitro toxicology. Food Chem. Toxicol., 40:283-326.
128. Davila, J. C., Rodriguez, R. J., Melchert, R. B., and Acosta, D. (1998): Predictive value of in vitro model systems in toxicology. Annu. Rev. Pharmacol. Toxicol., 38:63-96.
129. Lake, B. G. (1997): In vitro methods. In: Comprehensive Toxicology. Vol. 9. Hepatic and Gastrointestinal Toxicology, edited by R. S. McCuskey and D. L. Earnest. Pergamon Press, New York, pp. 233-246.
130. Damian, P., and Raabe, O. G. (1996): Toxicokinetic modeling of dose-dependent formate elimination in rats: in vivo-in vitro correlations using the perfused rat liver. Toxicol. Appl. Pharmacol., 139:22-32.
131. Gonzalez, F. J., and Korzekwa, K. R. (1995): Cytochrome P450 expression systems. Annu. Rev. Pharmacol. Toxicol., 35:369-390.
132. Ploemen, J.-P. H. T. M., Wormhoudt, L. W., Haenen, G. R. M. M., Oudshoorn, M. J., Commandeur, J. N. M., Vermeulen, N. P. E., de Waziers, I., Beaune, P. H., Watabe, T., and van Bladeren, P. J. (1997): The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: the case of ethylene dibromide. Toxicol. Appl. Pharmacol., 143:56-69.
133. Houston, J. B., and Carlile, D. J. (1997): Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab. Rev., 29:891-922.
134. Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., and Sugiyama, Y. (1998): Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol, 38:461-499.
135. Worboys, P. D., Bradbury, A., and Houston, J. B. (1994): Kinetics of drug metabolism in rat liver slices: rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds. Drug Metab. Disp., 23:393-397.
136. Worboys, P. D., Bradbury, A., and Houston J. B. (1996): Kinetics of drug metabolism in rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes. Drug Metab. Disp., 24:676-681.
137. Olinga, P, Merema, M., Hof, I. H., de Jong, K. P., Slooff, M. J. H., Meijer, D. K. F., and Groothuis, G. M. M. (1997): Effect of human liver source on the functionality of isolated hepatocytes and liver slices. Drug Metab. Disp., 26: 5-11.
138. Kedderis, G. L., and Held, S. D. (1996): Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice and humans, Toxicol. Appl. Pharmacol., 140:124-130.
139. Flamm, W. G., and Lorentzen, R. J. (1987): The use of in vitro methods in safety evaluation, In Vitro Toxicol., 1:1-3.
140. Lipscomb, J. C. and Ohanian, E. V. (2007): Toxicokinetics and Risk Assessment. Informa Healthcare Press, New York.